Urachal carcinoma: Surgical and chemotherapeutic options

Expert Review of Anticancer Therapy

Volumn 6, Issue 12, 2006, Pages 1715-1721

  Siefker Radtke, Arlene ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 fluorouracil; Adenocarcinoma; Bladder cancer; Chemotherapy; Cisplatin; Clinical trials; Gemcitabine; Surgery; Urachal

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN; PACLITAXEL; VINBLASTINE;

BLADDER BIOPSY; BLADDER CARCINOMA; BLADDER SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOSCOPY; DISEASE MARKER; DRUG RESPONSE; HEMATURIA; HISTOPATHOLOGY; HUMAN; LAPAROSCOPIC SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK FACTOR; SYSTEMIC THERAPY; URACHUS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; CYSTECTOMY; DEOXYCYTIDINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUOROURACIL; HEMATURIA; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RISK FACTORS; UMBILICUS; URACHAL CYST; URACHUS; URINARY BLADDER NEOPLASMS;

EID: 33846102175     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.12.1715     Document Type: Review

References (29)

1. Sheldon CA, Clayman RV, Gonzalez R et al. Malignant urachal lesions. J. Urol. 131, 1-8 (1984).
2. Henly DR, Farrow GM, Zincke H. Urachal cancer: role of conservative surgery. Urology 42, 635-639 (1993).
3. Siefker-Radtke AO, Gee J, Shen Y et al. Multimodality management of urachal carcinoma. The M. D. Anderson Cancer Center experience. J. Urol. 169, 1295-1298 (2003).
4. Wright JL, Porter MP, Li CI et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 107, 721-728 (2006).
5. Ashley RA, Inman BA, Sebo TJ et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 107, 712-720 (2006).
6. Schubert GE, Pavkovic MB, Bethke-Bedurftig BA. Tubular urachal remnants in adult bladders. J. Urol. 127, 40-42 (1982).
7. Begg RC. The urachus: anatomy, histology, and development. J. Anat. 64, 170 (1930).
8. Hammond G, Yglesias L, Davis J. Urachus, its anatomy and associated fasciae. Anat. Rec. 80, 271 (1941).
9. Johnson DE, Hodge GB, Abdul-Karim FW et al. Urachal carcinoma. Urology 26, 218-221 (1985).
10. Grignon DJ, Ro JY, Ayala AG et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 67, 2165-2172, (1991).
11. Shaw JL, Gislason GJ, Imbriglia JE. Transition of cystitis glandularis to primary adenocarcinoma of the bladder. J. Urol. 79, 815 (1958).
12. Wheeler J, Hill WT. Adenocarcinoma involving the urinary bladder. Cancer 7, 119 (1954).
13. Mostofi FK, Thomson RV, Dean ALJ. Mucous adenocarcinoma of the urinary bladder. Cancer 8, 741-758 (1955).
14. Siefker-Radtke AO, Czerniak BA, Dinney CP, Millikan RE. Uncommon cancers of the bladder. In: Textbook of Uncommon Cancer, Third Edition. Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG (Eds). John Wiley & Sons, NJ, USA 18-26 (2006).
15. Takeuchi M, Matsuzaki K, Yoshida S et al. Imaging findings of urachal mucinous cystadenocarcinoma associated with pseudomyxonia peritonei. Acta Radiologica 45, 348-350 (2004).
16. Kikuno N, Urakami S, Shigeno K et al. Urachal carcinoma associated with increased carbohydrate antigen 19-9 and carcinoembryonic antigen. J. Urol. 166, 604 (2001).
17. Guarnaccia S. Adenocarcinoma of the urachus associated with elevated levels of CA 125. J. Urol. 145, 140-141 (1991).
18. Milhoua PM, Knoll A, Bleustein CB et al. Laparoscopic partial cystectomy for treatment of adenocarcinoma of the urachus. Urology 67(2), 423.E15-423.E17 (2006).
19. Wadhwa P, Kolla SB, Hernal AK. Laparoscopic en bloc partial cystectomy with bilateral pelvic lymphadenectomy for urachal adenocarcinoma. Urology 67, 837-843, (2006).
20. Madeb R, Knopf JK, Nicholson C et al. The use of robotically assisted surgery for treating urachal anomalies Br. J. Urol. Int. 98, 838-842 (2006).
21. Herr HW. Urachal carcinoma: the case for extended partial cystectomy. J. Urol. 151, 365-356 (1994).
22. Pinthus JH, Haddad R, Trachtenberg J et al. Population based survival data on urachal tumors. J. Urol. 175, 2042-2047 (2006).
23. Lane V. Prognosis in carcinoma of the urachus. Eur. Urol. 2, 282-283 (1976).
24. Kakizoe T. Adenocarcinoma of urachus. Report of 7 cases and review of literature. Urology 21, 360-366 (1983).
25. Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 26, 252-255 (1985).
26. Siefker-Radtke AO, Millikan RE, Tu SM et al. Phase III trial of fluorouracil, interferon α-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J. Clin. Oncol. 20, 1361-1367 (2002).
27. Kojima Y, Yamada Y, Kamisawa H et al. Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy. Int. J. Urol. 13, 1123-1125 (2006).
28. Kume H, Tomita K, Takahashi S et al. Irinotecan as a new agent for urachal cancer. Urol. Int. 76, 281-282 (2006).
29. Galsky MD, Iasonos A, Mironov S et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non-transitional cell carcinomas of the urothelial tract. 24(Suppl. 18), 4542 J. Clin. Oncol. (2006).